CELLECTAR BIOSCIENCES INC (CLRB) Stock Overview
NASDAQ:CLRB - US15117F8077 - Common Stock
CLRB Key Statistics, Chart & Performance
The current stock price of CLRB is 4.87 USD. In the past month the price increased by 3.18%. In the past year, price decreased by -92.62%.
CLRB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.87 | 371.68B | ||
| AMGN | AMGEN INC | 13.19 | 154.89B | ||
| GILD | GILEAD SCIENCES INC | 14.6 | 140.17B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.08 | 100.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 61.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.53B | ||
| ARGX | ARGENX SE - ADR | 76.83 | 43.59B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.16 | 36.38B | ||
| INSM | INSMED INC | N/A | 28.77B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.04B | ||
| NTRA | NATERA INC | N/A | 23.09B | ||
| BIIB | BIOGEN INC | 8.26 | 19.38B |
Related stock screener links
About CLRB
Company Profile
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The company is headquartered in Florham Park, New Jersey and currently employs 11 full-time employees. The company went IPO on 2005-05-20. The firm is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
Company Info
CELLECTAR BIOSCIENCES INC
100 Campus Drive
Florham Park NEW JERSEY 07932 US
CEO: JamesV.Caruso
Employees: 11
Phone: 16084418120
CELLECTAR BIOSCIENCES INC / CLRB FAQ
What is the stock price of CELLECTAR BIOSCIENCES INC today?
The current stock price of CLRB is 4.87 USD. The price increased by 3.84% in the last trading session.
What is the ticker symbol for CELLECTAR BIOSCIENCES INC stock?
The exchange symbol of CELLECTAR BIOSCIENCES INC is CLRB and it is listed on the Nasdaq exchange.
On which exchange is CLRB stock listed?
CLRB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CELLECTAR BIOSCIENCES INC stock?
10 analysts have analysed CLRB and the average price target is 85.68 USD. This implies a price increase of 1659.34% is expected in the next year compared to the current price of 4.87. Check the CELLECTAR BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CELLECTAR BIOSCIENCES INC worth?
CELLECTAR BIOSCIENCES INC (CLRB) has a market capitalization of 15.54M USD. This makes CLRB a Nano Cap stock.
How many employees does CELLECTAR BIOSCIENCES INC have?
CELLECTAR BIOSCIENCES INC (CLRB) currently has 11 employees.
What are the support and resistance levels for CELLECTAR BIOSCIENCES INC (CLRB) stock?
CELLECTAR BIOSCIENCES INC (CLRB) has a support level at 4.33 and a resistance level at 5.6. Check the full technical report for a detailed analysis of CLRB support and resistance levels.
Should I buy CELLECTAR BIOSCIENCES INC (CLRB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CLRB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CLRB, evaluating the profitability, health, valuation and growth aspects
- CELLECTAR BIOSCIENCES INC (CLRB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CELLECTAR BIOSCIENCES INC (CLRB) Sales and EPS estimates to see what analysts future expectations are.
- CELLECTAR BIOSCIENCES INC (CLRB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CELLECTAR BIOSCIENCES INC (CLRB) Insider and Institutional Ownership to learn about the owners and their transactions.
- CELLECTAR BIOSCIENCES INC (CLRB) Stock Chart to make your own analysis
- CELLECTAR BIOSCIENCES INC (CLRB) Latest news and press-releases to stay up to date.
Does CELLECTAR BIOSCIENCES INC (CLRB) stock pay dividends?
CLRB does not pay a dividend.
When does CELLECTAR BIOSCIENCES INC (CLRB) report earnings?
CELLECTAR BIOSCIENCES INC (CLRB) will report earnings on 2025-10-27, before the market open.
What is the Price/Earnings (PE) ratio of CELLECTAR BIOSCIENCES INC (CLRB)?
CELLECTAR BIOSCIENCES INC (CLRB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.79).
What is the Short Interest ratio of CELLECTAR BIOSCIENCES INC (CLRB) stock?
The outstanding short interest for CELLECTAR BIOSCIENCES INC (CLRB) is 4.6% of its float. Check the ownership tab for more information on the CLRB short interest.
CLRB Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CLRB. When comparing the yearly performance of all stocks, CLRB is a bad performer in the overall market: 98.66% of all stocks are doing better.
CLRB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CLRB. While CLRB seems to be doing ok healthwise, there are quite some concerns on its profitability.
CLRB Financial Highlights
Over the last trailing twelve months CLRB reported a non-GAAP Earnings per Share(EPS) of -9.79. The EPS decreased by -342.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -212.28% | ||
| ROE | -389.34% | ||
| Debt/Equity | 0 |
CLRB Forecast & Estimates
10 analysts have analysed CLRB and the average price target is 85.68 USD. This implies a price increase of 1659.34% is expected in the next year compared to the current price of 4.87.